EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte Studie

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer

John V Heymach, Gerrina Ruiter, Myung-Ju Ahn, Nicolas Girard, Egbert F Smit, David Planchard, Yi-Long Wu, Byoung Chul Cho iD, Noboru Yamamoto, Joshua K Sabari, Yanqiu Zhao, Hai-Yan Tu und 8 weitere

New England Journal of Medicine · 19.06.2025 · 392 (23) · 2321-2333

DOI: 10.1056/nejmoa2503704 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, erschienen am 19.06.2025. Verfasst von John V Heymach und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErb-b2 Receptor Tyrosine KinasesTyrosine Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationProgression-Free SurvivalTrastuzumabImmunoconjugatesTreatment OutcomeCamptothecin

Substanzen

Erb-b2 Receptor Tyrosine KinasesTyrosine Kinase InhibitorsTrastuzumabImmunoconjugatesCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston.
  • Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam.
  • Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam.
  • Department of Hematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Institut Curie, Institut du Thorax Curie-Montsouris, Paris.
  • Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, France.

ORCID-Profile: Byoung Chul Cho

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Heymach, J. V., Ruiter, G., Ahn, M. J., Girard, N., Smit, E. F., Planchard, D., Wu, Y. L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H. Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., Zugazagoitia, J., & Beamion LUNG-1 Investigators (2025). Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 392(23), 2321-2333. https://doi.org/10.1056/nejmoa2503704

Vancouver

Heymach JV, Ruiter G, Ahn MJ, Girard N, Smit EF, Planchard D, et al. Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2025;392(23):2321-2333. doi:10.1056/nejmoa2503704

BibTeX
@article{Heymach2025,
  author = {Heymach, John V and Ruiter, Gerrina and Ahn, Myung-Ju and Girard, Nicolas and Smit, Egbert F and Planchard, David and Wu, Yi-Long and Cho, Byoung Chul and Yamamoto, Noboru and Sabari, Joshua K and Zhao, Yanqiu and Tu, Hai-Yan and Yoh, Kiyotaka and Nadal, Ernest and Sadrolhefazi, Behbood and Rohrbacher, Maren and von Wangenheim, Ute and Eigenbrod-Giese, Sabina and Zugazagoitia, Jon and Beamion LUNG-1 Investigators, Beamion LUNG-1 Investigators},
  title = {Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {23},
  pages = {2321--2333},
  doi = {10.1056/nejmoa2503704}
}
Kostenlos starten →